FDA Classifies Endoscopic Suturing Device for Weight Loss Into Class II, Opening 510(k) Pathway for Future Competitors

What this means for your practice

For medspas, weight loss clinics, and telehealth platforms offering obesity or metabolic health services, this FDA classification signals a maturing regulatory landscape for endoscopic bariatric procedures. As Class II clearance lowers the barrier for future device entrants via 510(k), the market for endoscopic gastric procedures is likely to see increased competition and device availability. Practices that partner with or refer patients to endoscopic weight loss programs should understand that devices cleared through the 510(k) pathway using this De Novo as a predicate will carry special controls — meaning specific performance standards, labeling requirements, and post-market surveillance obligations apply. Telehealth operators discussing or promoting endoscopic weight loss options to patients should ensure their clinical and marketing content accurately reflects FDA device classification status and avoids implying equivalency between classified devices and uncleared alternatives.

FDA Finalizes Class II Classification for Endoscopic Suturing Device Used in Weight Loss Procedures

The U.S. Food and Drug Administration (FDA) has issued a final order classifying the endoscopic suturing device for altering gastric anatomy for weight loss into Class II (special controls) under 21 CFR Part 876. The order, published May 28, 2026, in the Federal Register (Docket No. FDA-2026-N-5200), formalizes a De Novo classification that was applicable as of July 12, 2022.

This action has meaningful implications for healthcare businesses operating in the rapidly growing weight management and metabolic health space — including telehealth platforms, medspas, obesity medicine practices, and any provider that refers patients to or promotes endoscopic bariatric options.

What Is De Novo Classification?

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), any medical device not in commercial distribution before May 28, 1976 — known as a "postamendments device" — is automatically classified as Class III by operation of law. Class III devices require the most rigorous regulatory review: Premarket Approval (PMA), which involves extensive clinical trial data and a lengthy FDA review process.

However, FDA has authority under section 513(f)(2) of the FD&C Act to reclassify a device through the De Novo process when it determines that Class II controls are sufficient to provide reasonable assurance of safety and effectiveness. This is exactly what FDA did here.

The De Novo process can be initiated in one of two ways: - The device sponsor first submits a 510(k), receives a Class III order, and then requests De Novo classification. - Alternatively, if the sponsor determines no legally marketed predicate device exists, it may request De Novo classification directly.

FDA is required to classify the device within 120 days of receiving a De Novo request.

The Apollo Endosurgery Request

This classification originated from a De Novo request submitted by Apollo Endosurgery, Inc. on September 30, 2021, covering its APOLLO ESG System, APOLLO ESG SX System, APOLLO REVISE System, and APOLLO REVISE SX System — devices designed for endoscopic suturing to alter gastric anatomy for the purpose of weight loss.

FDA reviewed the request and determined that Class II special controls — rather than full Class III Premarket Approval — provide a reasonable assurance of safety and effectiveness for this device type. The special controls applicable to this device type are codified as part of 21 CFR Part 876.

What Changes With Class II Classification?

Class II devices are subject to special controls, which may include: - Specific performance standards - Mandatory post-market surveillance requirements - Particular labeling and patient disclosure requirements - FDA guidance documents that define acceptable testing and design parameters

Critically, by classifying this device type via the De Novo process, FDA has established a regulatory predicate. This means future manufacturers of substantially equivalent endoscopic suturing devices for gastric anatomy alteration can seek market clearance through the 510(k) premarket notification pathway — a significantly less burdensome process than PMA — rather than submitting a new De Novo request or a full PMA.

As FDA noted in the order, this action is intended in part to "enhance patients' access to beneficial innovative devices" by reducing regulatory burdens.

Implications for Weight Loss and Metabolic Health Programs

The endoscopic bariatric space — including procedures like endoscopic sleeve gastroplasty (ESG) — has grown substantially as patients and providers seek less invasive alternatives to traditional bariatric surgery. Telehealth platforms and medspas are increasingly active in obesity medicine, often serving as the first point of contact for patients exploring weight loss options.

Here is what this FDA action means practically:

1. Market Expansion Is Likely With the 510(k) pathway now available for substantially equivalent devices, additional manufacturers can bring competing products to market more efficiently. Healthcare businesses should expect a broader range of cleared endoscopic weight loss devices to become available over time.

2. Device Status Matters for Referrals and Marketing If your telehealth platform, medspa, or practice refers patients to endoscopic weight loss procedures or promotes them as a service category, you should be aware of the FDA clearance status of any specific device involved. Marketing claims tied to uncleared devices — or claims that imply FDA approval when only clearance exists — carry regulatory and FTC risk.

3. Special Controls Apply to Cleared Devices Any device cleared via 510(k) using this De Novo as a predicate must comply with the special controls established under 21 CFR Part 876. Practices acquiring or recommending these devices should confirm the device's cleared indications and that it is being used consistent with its labeling.

4. Telehealth Consultation Scope Telehealth providers discussing endoscopic bariatric options with patients should ensure their clinical protocols reflect FDA-cleared indications. Recommending or prescribing use of devices outside cleared indications — or facilitating access to unapproved devices — creates both regulatory and liability exposure.

Regulatory Reference

This final order amends 21 CFR Part 876 (Gastroenterology-Urology Devices) and is codified under FDA's De Novo classification authority at section 513(f)(2) of the FD&C Act. The docket is available at the Federal Register under Docket No. FDA-2026-N-5200.

Effective Date: May 28, 2026 Classification Applicable Date: July 12, 2022

Bottom Line for Compliance Teams

This is not an enforcement action — it is a device classification order that reshapes the regulatory pathway for an emerging category of weight loss devices. For healthcare businesses in the obesity medicine, telehealth, and medspa space, the key compliance takeaway is straightforward: understand the FDA clearance status of any device you use, recommend, or promote, and ensure all clinical and marketing activity aligns with cleared indications and applicable special controls.

Source: FDA — Rule: Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Suturing Device for Altering Gastric Anatomy for Weight Loss · 2026-05-28